Abstract:MicroRNAs (miRNAs) are small, non-coding regulatory RNAs that post-transcriptionally regulate gene expression. These conserved molecules are highly expressed in the brain, being essential for neuronal function and survival. miRNA profiles are significantly altered in Alzheimer's disease (AD) patient brains. We have previously shown that tauroursodeoxycholic acid (TUDCA) is a strong neuroprotective agent in several AD experimental models. In addition, bile acids modulate both mRNA and miRNA expression in the rat liver. Nevertheless, the therapeutic role of TUDCA in AD pathology has not yet been ascertained. The present study was designed to identify miRNAs differentially expressed in wild-type and APP/PS1 transgenic mice, as well as elucidate the role of TUDCA in modulating miRNAs potentially associated with AD. We carried out highly sensitive expression profiling of 1140 miRNAs on samples obtained from the hippocampus and frontal cortex of male APP/PS1 transgenic mice and wild-type littermates fed diets containing 0.4 percent TUDCA, or no bile acid, for 6 months. Validation was performed by qRT-PCR. APP/PS1 mice brains showed significant and large fold-change differential expression of 46 miRNAs including miR-295, -302c, -599, and -615, relative to wild-type mice. In addition, significant differences were also detected in 28 miRNAs in the direct comparison of untreated and TUDCA-treated APP/PS1 mice. Finally, in silico analysis identified putative target genes for specific miRNAs deregulated in APP/PS1 mice and modulated by TUDCA. Pathway enrichment within these putative targets revealed that miRNAs found altered in APP/PS1 mice are potentially involved in axon guidance mechanisms, long-term potentiation and/or depression, glutamate metabolism, and apoptosis. Interestingly, amyloid precursor protein (APP) 3'UTR is potentially targeted by miR-295, which expression was significantly decreased in the cortex of APP/PS1 mice. In contrast, miR-599 was upregulated in the brain of APP/PS1 mice and potentially targets the low-density lipoprotein (LDL) receptor-related protein 6 (LRP6) 3'UTR involved in Aβ clearance. Notably, miR-599 expression was decreased by TUDCA. miRNA profiling of APP/PS1 mice provides an appealing approach to address how changes in miRNA profiles translate into biological functions in AD pathological context. Modulation of AD-associated miRNAs by TUDCA may represent a potential therapeutic strategy for prevention and treatment of the disease.

Identification of Circulating Mir-125B As a Potential Biomarker of Alzheimer's Disease in APP/PS1 Transgenic Mouse

Genome-wide Analysis of Mirna Signature in the APPswe/PS1ΔE9 Mouse Model of Alzheimer's Disease.

Circulating Mir-125B As a Biomarker of Alzheimer's Disease

MicroRNA-135a and -200B, Potential Biomarkers for Alzheimer׳s Disease, Regulate Β Secretase and Amyloid Precursor Protein.

Analysis of Serum Β-Amyloid Peptides, Α2-Macroglobulin, Complement Factor H, and Clusterin Levels in APP/PS1 Transgenic Mice During Progression of Alzheimer's Disease.

Age-related changes in brain metabolites and cognitive function in APP/PS1 transgenic mice.

Exosomes Mediate APP Dysregulation <i>via</i> APP-miR-185-5p Axis

Increased Plasma Levels of Macrophage Migration Inhibitory Factor in a Transgenic Mouse Model of Alzheimer’s Disease

Mir-124 Downregulates Bace 1 and Alters Autophagy in App/Ps1 Transgenic Mice

P3‐046: Understanding Brain Microrna Profiling in the Double Transgenic APP/PS1 Mouse Model of Alzheimer's Disease

Multiple Inflammatory Profiles of Microglia and Altered Neuroimages in APP/PS1 Transgenic AD Mice.

Preliminary study on early diagnosis of Alzheimer's disease in APP/PS1 transgenic mice using multimodal magnetic resonance imaging

MiRNA-15b and Mirna-125B Are Associated with Regional Aβ-PET and FDG-PET Uptake in Cognitively Normal Individuals with Subjective Memory Complaints

Identification of potential therapeutic and diagnostic characteristics of Alzheimer disease by targeting the miR-132-3p/FOXO3a-PPM1F axis in APP/PS1 mice

MicroRNA-16 targets amyloid precursor protein to potentially modulate Alzheimer's-associated pathogenesis in SAMP8 mice.

Dynamic Changes in the Levels of Amyloid-β42 Species in the Brain and Periphery of APP/PS1 Mice and Their Significance for Alzheimer’s Disease

MicroRNA-4722-5p and microRNA-615-3p serve as potential biomarkers for Alzheimer's disease

Novel Plasma Mirnas As Biomarkers and Therapeutic Targets of Alzheimer's Disease at the Prodromal Stage.

MicroRNA-455-3P as a peripheral biomarker and therapeutic target for mild cognitive impairment and Alzheimer's disease

Serum MicroRNA Profiles Serve As Novel Biomarkers for the Diagnosis of Alzheimer’s Disease

Dysregulation and Diagnostic Potential of Microrna in Alzheimer’s Disease